Hyundai Pharmaceutical Co., Ltd. (004310.KS)
KRW 3710.0
(-2.62%)
KRW 3710.0
(-2.62%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 13.2 Billion KRW | 146.83% |
| 2022 | 10.04 Billion KRW | 220.65% |
| 2021 | 273.16 Million KRW | -57.35% |
| 2020 | 7.33 Billion KRW | 6.38% |
| 2019 | 5.58 Billion KRW | 802.28% |
| 2018 | 726.44 Million KRW | -80.3% |
| 2017 | 1.78 Billion KRW | -6.79% |
| 2016 | 4.32 Billion KRW | 36.88% |
| 2015 | 7.53 Billion KRW | -26.72% |
| 2014 | 4.2 Billion KRW | -0.36% |
| 2013 | 4.23 Billion KRW | 278.01% |
| 2012 | -2.58 Billion KRW | -148.79% |
| 2011 | 5.75 Billion KRW | 118.83% |
| 2010 | 2.21 Billion KRW | -66.44% |
| 2009 | 5.73 Billion KRW | 56.76% |
| 2008 | 7.18 Billion KRW | 25.21% |
| 2007 | 9.1 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 2.29 Billion KRW | 31.49% |
| 2024 Q3 | 568.53 Million KRW | -78.0% |
| 2024 Q1 | 2.02 Billion KRW | 96.92% |
| 2023 Q3 | 3.03 Billion KRW | -29.64% |
| 2023 Q2 | 4.3 Billion KRW | 30.16% |
| 2023 Q1 | 3.3 Billion KRW | 501.36% |
| 2023 Q4 | 61.23 Million KRW | -97.98% |
| 2023 FY | - KRW | 146.83% |
| 2022 Q3 | 4.16 Billion KRW | 22.28% |
| 2022 FY | - KRW | 220.65% |
| 2022 Q4 | -824.61 Million KRW | -119.81% |
| 2022 Q2 | 3.4 Billion KRW | 0.61% |
| 2022 Q1 | 3.38 Billion KRW | 186.94% |
| 2021 Q2 | 1.46 Billion KRW | 1858.76% |
| 2021 Q3 | 3.18 Billion KRW | 117.42% |
| 2021 Q1 | 74.82 Million KRW | -93.42% |
| 2021 FY | - KRW | -57.35% |
| 2021 Q4 | -3.89 Billion KRW | -222.15% |
| 2020 Q1 | 1.08 Billion KRW | -46.18% |
| 2020 Q4 | 1.13 Billion KRW | 555.22% |
| 2020 Q2 | 5.06 Billion KRW | 367.42% |
| 2020 Q3 | 173.42 Million KRW | -96.57% |
| 2020 FY | - KRW | 6.38% |
| 2019 Q3 | 1.42 Billion KRW | 25.86% |
| 2019 FY | - KRW | 802.28% |
| 2019 Q2 | 1.12 Billion KRW | -26.73% |
| 2019 Q4 | 2.01 Billion KRW | 41.5% |
| 2019 Q1 | 1.54 Billion KRW | 152.47% |
| 2018 Q1 | 1.42 Billion KRW | 13.19% |
| 2018 Q2 | 1.21 Billion KRW | -14.75% |
| 2018 Q3 | 1.07 Billion KRW | -11.03% |
| 2018 FY | - KRW | -80.3% |
| 2018 Q4 | -2.93 Billion KRW | -372.22% |
| 2017 FY | - KRW | -6.79% |
| 2017 Q4 | 1.25 Billion KRW | 22.44% |
| 2017 Q3 | 1.02 Billion KRW | 6.3% |
| 2017 Q2 | 966.14 Million KRW | -63.88% |
| 2017 Q1 | 2.67 Billion KRW | 177.23% |
| 2016 Q1 | 1.1 Billion KRW | 134.16% |
| 2016 Q2 | 1.13 Billion KRW | 2.16% |
| 2016 Q4 | 964.79 Million KRW | -1.91% |
| 2016 Q3 | 983.55 Million KRW | -13.12% |
| 2016 FY | - KRW | 36.88% |
| 2015 Q1 | 1.75 Billion KRW | 53.06% |
| 2015 FY | - KRW | -26.72% |
| 2015 Q4 | -3.24 Billion KRW | -195.85% |
| 2015 Q3 | 3.38 Billion KRW | 348.08% |
| 2015 Q2 | 755.25 Million KRW | -57.08% |
| 2014 Q2 | 1.15 Billion KRW | 6.25% |
| 2014 Q1 | 1.08 Billion KRW | 242.77% |
| 2014 Q4 | 1.14 Billion KRW | 15.5% |
| 2014 FY | - KRW | -0.36% |
| 2014 Q3 | 995.37 Million KRW | -13.88% |
| 2013 Q1 | 926.8 Million KRW | 438.59% |
| 2013 Q2 | 1.25 Billion KRW | 35.59% |
| 2013 Q3 | 1.29 Billion KRW | 3.13% |
| 2013 Q4 | 317.34 Million KRW | -75.51% |
| 2013 FY | - KRW | 278.01% |
| 2012 Q3 | -226.99 Million KRW | 93.76% |
| 2012 FY | - KRW | -148.79% |
| 2012 Q1 | 1.4 Billion KRW | -42.34% |
| 2012 Q2 | -3.63 Billion KRW | -359.69% |
| 2012 Q4 | -273.72 Million KRW | -20.58% |
| 2011 FY | - KRW | 118.83% |
| 2011 Q1 | 1.81 Billion KRW | 2501.65% |
| 2011 Q2 | 506.5 Million KRW | -72.05% |
| 2011 Q3 | 106.09 Million KRW | -79.05% |
| 2011 Q4 | 2.43 Billion KRW | 2190.97% |
| 2010 Q3 | -266.97 Million KRW | -124.68% |
| 2010 Q1 | 1.47 Billion KRW | -26.83% |
| 2010 Q4 | -75.44 Million KRW | 71.74% |
| 2010 FY | - KRW | -66.44% |
| 2010 Q2 | 1.08 Billion KRW | -26.63% |
| 2009 FY | - KRW | 56.76% |
| 2009 Q4 | 2.01 Billion KRW | 59.09% |
| 2009 Q3 | 1.26 Billion KRW | 64.81% |
| 2009 Q2 | 768.6 Million KRW | -46.44% |
| 2009 Q1 | 1.43 Billion KRW | 195.75% |
| 2008 Q3 | -1.16 Billion KRW | -137.2% |
| 2008 Q4 | -1.49 Billion KRW | -29.07% |
| 2008 Q2 | 3.12 Billion KRW | -17.47% |
| 2008 Q1 | 3.78 Billion KRW | 87.58% |
| 2008 FY | - KRW | 25.21% |
| 2007 Q2 | 3.46 Billion KRW | 6.89% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q3 | -5.37 Billion KRW | -255.23% |
| 2007 Q4 | 2.01 Billion KRW | 137.51% |
| 2007 Q1 | 3.23 Billion KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -171.895% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 90.656% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 120.628% |
| HANDOK Inc. | 35.06 Billion KRW | 62.33% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 1374.35% |
| Yuhan Corporation | 127.43 Billion KRW | 89.634% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | 64.794% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 160.909% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 95.915% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | -164.704% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 12.625% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -286.135% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -191.834% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | 62.776% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -171.895% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 171.512% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | -101.521% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 126.799% |
| JW Holdings Corporation | 187.88 Billion KRW | 92.969% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 125.786% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 95.343% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 85.194% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 135.637% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | -11.682% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | 29.189% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -171.895% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | 75.971% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 91.99% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 85.194% |
| Yuhan Corporation | 127.43 Billion KRW | 89.634% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | 60.54% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | -72.678% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 82.851% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 85.194% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | 63.942% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 81.337% |
| CKD Bio Corp. | -1.63 Billion KRW | 910.184% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | 73.471% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | 59.432% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | 64.114% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 135.637% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 78.791% |
| Boryung Corporation | 114.28 Billion KRW | 88.442% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 143.213% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 12.625% |
| JW Lifescience Corporation | 50.82 Billion KRW | 74.012% |